Grand Rapids, Mich.-based medical device startup, Happe Spine, aims to launch in the spine and orthopedic market by early 2023 with its new implant material, according to a Nov. 23 report from MiBiz.
Happe Spine expects to receive FDA clearance within the next two to three months for its new porous, bioactive material that encourages bone growth, according to the report.
After FDA review, Happe plans to target hospitals, ASCs and orthopedic practices.
Last year, Happe closed on a $3.35 million series A funding round, and an additional $2 million round this year.